Eli Lilly (LLY) stock soars after FDA approves Foundayo - can this weight-loss pill drive massive growth as investors bet big on obesity drug boom

Eli Lilly (LLY) stock today: Eli Lilly's stock surged over 5% following the US FDA's approval of its new oral weight-loss drug, Foundayo. This marks a significant expansion for Lilly in the lucrative obesity market. Clinical trials showed substantial weight loss, and the drug's accessible pricing strategy is expected to boost its adoption, strengthening Lilly's portfolio.

Go to News Site